These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 26084402)

  • 1. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
    Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer.
    Karantanos T; Tanimoto R; Edamura K; Hirayama T; Yang G; Golstov AA; Wang J; Kurosaka S; Park S; Thompson TC
    Int J Cancer; 2014 Apr; 134(8):2003-13. PubMed ID: 24590455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
    Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y
    Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
    Yoo J; Park SS; Lee YJ
    J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
    Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
    Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
    Eftekhari S; Montazeri H; Tarighi P
    Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
    PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
    Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
    Gao Q; Zheng J
    Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.